Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2004-05-21
2011-12-27
Andres, Janet (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
08084495
ABSTRACT:
The diterpenic labdane 3-[2-[decahydro-6-hydroxy-5-(hydroxymethyl)-5,ha-dimethyl-2-methylene-1-naphthalenyl]ethylidene]-dihydro-4-hydroxy-2(3h)-furanone, chemically diagrammed asinhibits the synthesis of pro-inflammatory cytokines, activates the PPAR-gamma receptor and diminishes nuclear factor kappa B.The compound is useful to treat auto-immune diseases, for organ and tissue transplantation, and to treat immunodeficiency (e.g., AIDS).
REFERENCES:
patent: 5833994 (1998-11-01), Wheelock et al.
patent: 5883074 (1999-03-01), Boggs et al.
patent: 6140063 (2000-10-01), Wheelock et al.
patent: 6313269 (2001-11-01), Deen et al.
patent: 6410590 (2002-06-01), Nanduri et al.
patent: 6486196 (2002-11-01), Nanduri et al.
patent: 2002/0016324 (2002-02-01), Nanduri et al.
patent: 2002/0068098 (2002-06-01), Babish et al.
patent: 2002/0077350 (2002-06-01), Babish et al.
patent: 2003/0108628 (2003-06-01), Babish et al.
patent: 9617605 (1996-06-01), None
patent: WO96/17605 (1996-06-01), None
patent: 9830213 (1998-07-01), None
Samaha et al., “Effect of resiglitazone on lipids, adipokines, and inflammatory markers in nondiabetic patients with low high-density lipoprotein cholesterol and metabolic syndrome”, Journal of the American heart association, 2006, vol. 26, pp. 624-630.
Vasantha et al., “SIRT1 modulating compounds from high-throughput screening as anti-inflammatory and insulin-sensitizing agents”, Journal of biomolecular screening, 2006, vol. 11, pp. 959-967.
http:/familydoctor.org/online/famdocen/home/common/heartdisease/basics/826.printerview, (2005).
Saso et al., “Abnormal Glycosylation of α-Macroglobulin, A non-acute-phase protein, in patients with autoimmune diseases”, Inflammation, vol. 17, pp. 465-479, (1993).
Onat et al., “Metabolic syndrome: major impact on coronary risk in a polulation with low cholesterol levels—a prospective and cross-sectional evaluation”, Atherosclerosis, vol. 165, pp. 285-292, (2002).
Vickers et al. “Adult growth hormone treatment reduces hypertension and obesity induced by an adverse prenatal environment”, Journal of Endocrinology, vol. 175, pp. 615-623, (2002).
Panossian et al., “Effect of Andrographolide and Kan Jang fixed combination of extract SHA-10 and extract SHE-3—on proliferation of human lymphocytes, production of cytokines and immune activation markers in the whole blood cells culture”, Phytomedicine, vol. 9, pp. 598-605, (2002).
Smith et al., “PPAR-Y receptor agonists—a review of their role in diabetic management in Trinidad and Tobago”, Molecular and Cellular Biochemistry, 200, vol. 263, pp. 189-210, (2004).
Miterski et al., “Inhibitors in the NFkB cascade comprise prime candidate genes predisposing to multiple sclerosis, especially in selected combinations”, Genes and Immunity, 2002, vol. 3, pp. 211-219, (2002).
Daly et al., “Dietary carbohydrates and insulin sensitivity: a review of the evidence and clinical implications”, American Society for Clinical Nutrition, 1997, vol. 66, pp. 1072-1085, (1997).
H.Y. Cheung et al., “Determination of Bioactive Diterpinoids fromAndrographis paniculataby Micellar Electrokinetic Chromatography,” 930 J. Chromatog. 171-76 (Sep. 28, 2001) (Elsevier Science, publ.).
S.S. Handa et al., “Hepatoprotective Activity of Andrographolide fromAndrographis paniculataAgainst Carbontetrachloride,” 92 Indian J. Med. Res. 276-83 (Aug. 1990) (ISSN: 0971-5916).
P.P. Gupta et al., “Antiallergic Acivity of Andrographolides Isolated fromAndrographis paniculata(Burm. F) wall,” 36 Pharma. Biol. 72-74 (Jan. 1998).
X-F. Zhang et al., “Antihyperglycemic and Anti-Oxidant Properties ofAndrographis paniculatain Normal and Diabetic Rats,” 27 Clin Exper. Pharmacol. and Physiol. (2000).
Burgos Aguilera Rafael Agustin
Hancke Orozco Juan Luis
Andres Janet
Herbal Powers Corporation
Pharmaceutical Patent Attorneys, LLC
Rahmani Niloofar
LandOfFree
Composition of labdane diterpenes extracted from... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition of labdane diterpenes extracted from..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition of labdane diterpenes extracted from... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4267878